Nuevas vías de administración de Trastuzumab MIQUEL ÀNGEL SEGUÍ PALMER

Size: px
Start display at page:

Download "Nuevas vías de administración de Trastuzumab MIQUEL ÀNGEL SEGUÍ PALMER"

Transcription

1 Nuevas vías de administración de Trastuzumab MIQUEL ÀNGEL SEGUÍ PALMER

2 Trastuzumab, a humanized monoclonal antibody against the extracellular domain of the HER2 receptor, is the standard-of-care treatment for patients with early and advanced HER-2 positive breast cancer Rituximab and trastuzumab were the first monoclonal antibodies (mabs) approved for the treatment of cancer. In oncology, mabs are typically administered by intravenous (IV) infusion; however, this administration route faces some challenges

3 Challenges of Intravenous administration of mabs The need for trained personnel, dedicated infusion facilities, dose calculation, aseptic preparation of required infusion volumes, and extended post-infusion observation. Long infusion times and slow workflow for medical staff. Potential difficulties with IV catheter placements. Risk of infusion-related reactions and complications (e.g. relevant thromboembolic events, infections), leading to hospitalisation and additional costs. Costs associated with the placement of permanent IV lines.

4 Revenues of IV versus SC-administered anti-tnf-alpha treatments ( )

5 Subcutaneous (SC) administration can potentially overcome many of these challenges. Although administration-associated reactions (AARs) may occur with SC administration, they are likely to be less severe than IV-associated infusion-related reactions, given the more gradual absorption of the SC formulation. SC formulations may be more convenient for patients, offering potential improvements in quality of life and treatment adherence. In oncology, SC administration of mabs has been shown to reduce administration times and health-care costs relative to IV infusion.

6 However, the biggest challenge with SC formulations has been the ability to deliver the required volume of drug to patients. The extracellular matrix, which maintains tissue architecture and controls diffusion/molecule flow, limits drug volumes to 1 2 ml, with volumes >2ml causing tissue distortion and pain. The extracellular matrix is composed of a structural network of fibrous proteins (collagen and elastin)embedded within a hydrated viscoelastic gel, composed of glycosaminoglycans that are complex linear polysaccharides characterized by repeating disaccharide structures of an N-substituted hexosamine and an uronic acid, including hyaluronan (hyaluronic acid9, chondroitin sulfate, dermatan sulfate, heparin sulfate, heparin and keratin sulfate.

7 Development of a SC Formulation of Trastuzumab These hurdles have been overcome by concentrating IV formulations 12-fold and adding recombinant human hyaluronidase (rhuph20). By hydrolysing hyaluronan, rhuph20 reversibly opens the interstitial space in SC tissue and allows the installation of >2 3 ml.

8 Administration site before and immediately after infusion without and with rhuph20

9 Clinical trials of subcutaneous trastuzumab in patients with HER2+ early stage breast cancer

10 Comparison of SC and IV Administration of Trastuzumab. Phase I/Ib Trial A subcutaneous trastuzumab dose of 8 mg/kg was found to result in exposure comparable with the intravenous trastuzumab dose of 6 mg/kg. The subcutaneous formulation was well tolerated. Wynne C et al. J Clin Pharmacol. 2013;53(2):

11 Development of a Fixed-Dose Subcutaneous Formulation of Trastuzumab The fixed dose of subcutaneous trastuzumab given every 3 weeks was determined by pharmacokinetic modelling of data from the phase I. 600-mg trastuzumab s.c. dose, administered thriceweekly (Q3W) without a loading dose, would provide C trough (predose Cycle 8) and area under the time concentration curve (AUC 0 21 days, Cycle 7) at least as high as Q3W i.v. administration. Hourcade-Potelleret F et al. CPT Pharmacometrics Syst. Pharmacol. (2014) 3, e87

12 HannaH Trial Fixed Dose for Trastuzumab SC Comparable Efficacy Expected Based on PK Profiles

13 HannaH Trial Randomized Open-Label Phase III Non-Inferiority Study to Compare the PK, Efficacy and Safety of Trastuzumab SC and IV in HER2-Positive EBC

14 Baseline patient demographic and tumour characteristics Ismael G, et al. Lancet Oncol. 2012;13(9);

15 HannaH Trial: Efficacy Results Ismael G, et al. Lancet Oncol. 2012;13(9);

16 HannaH Trial: Safety and Tolerability Ismael G, et al. Lancet Oncol. 2012;13(9);

17 HannaH Trial: Anti-Drug Antibodies (ADAs) Ismael G, et al. Lancet Oncol. 2012;13(9);

18 HannaH Trial Demonstrated the noninferiority of the fixed-dose SC trastuzumab formulation vs the IV formulation by meeting the co-primary endpoints of noninferior serum trough concentration and pathologic complete response (pcr) with neo)adjuvant SC trastuzumab via manual injection compared to IV The overall safety profile of the fixed-dose SC trastuzumab formulation was comparable to that of IV trastuzumab, and consistent with the known safety profile of trastuzumab in early breast cancer

19 PrefHer Trial To investigate benefits of the trastuzumab SC formulation, the international, multicenter, openlabel, randomized, two-cohort, two-arm PrefHer study was designed to assess patients preferences for trastuzumab SC or IV in the adjuvant breast cancer setting.

20 PrefHer Trial 1. Pivot X, et al. Lancet Oncol. 2013;14(10): Pivot X, et al. Cancer Res. 2013;73(24 Suppl): Abstract P

21 Cohort 1: Trastuzumab SC administered via SID Patient Preferences High preference for trastuzumab SC was maintained, irrespective of whether patients were de novo or non-de novo trastuzumab IV prior to study enrolment. Pivot X, et al. Lancet Oncol. 2013;14(10):962-70

22 Cohort 1: Trastuzumab SC administered via SID Primary Reasons for Patients Preferences Pivot X, et al. Lancet Oncol. 2013;14(10):962-70

23 Cohort 1: Trastuzumab SC administered via SID Strength of Patients Preferences Pivot X, et al. Lancet Oncol. 2013;14(10):962-70

24 Cohort 1: Trastuzumab SC administered via SID Healthcare Professional (HCP) Satisfaction Pivot X, et al. Lancet Oncol. 2013;14(10):962-70

25 Cohort 2: Trastuzumab SC administered via SC hand-held syringe Patients Preferences Pivot X, et al. Cancer Res. 2013;73(24 Suppl): Abstract P

26 Cohort 2: Trastuzumab SC administered via SC hand-held syringe Strength of Patients Preferences Pivot X, et al. Cancer Res. 2013;73(24 Suppl): Abstract P

27 Cohort 2: Trastuzumab SC administered via SC hand-held syringe Healthcare Professional (HCP) Satisfaction Pivot X, et al. Cancer Res. 2013;73(24 Suppl): Abstract P

28 Patients in the PrefHer study had a very strong preference for SC over IV trastuzumab, mainly because it saved them time and caused them less pain/discomfort/side effects than IV administration. Confirmed advantages of SC trastuzumab administration include: - Improved patient convenience - Reduced use of hospital resources and the time of healthcare professionals There was a high level of healthcare professional satisfaction with SC trastuzumab. The overall safety profile of 4 cycles of trastuzumab SC and 4 cycles of trastuzumab IV observed during the crossover period in the PrefHer study was consistent with the known safety profile of trastuzumabin early breast cancer. Safety data did not raise any safety concerns thus far.

29 SafeHer Trial Design

30 Patient time associated with IV and SC trastuzumab formulations Lopez-Vivanco G et al. 19th Congress of the European Association of Hospital Pharmacists March 2014,

31 Conclusions For patients receiving treatment over prolonged periods, SC administration offers significant benefits over IV administration and is considered convenient. SC formulations of trastuzumab can potentially improve convenience and quality of life for patients and provide cost savings to health-care systems. Patient preference and safety results from PrefHer, combined with efficacy, pharmacokinetic, and safety results from HannaH, suggest that a fixed dose of 600 mg trastuzumab SC every 3 weeks, for about 5 min, is a validated, well tolerated, and preferred option for the treatment of HER2-positive breast cancer

32

33

Clinical and statistical considerations of bridging approaches to alternative dosing regimen or formulations

Clinical and statistical considerations of bridging approaches to alternative dosing regimen or formulations Clinical and statistical considerations of bridging approaches to alternative dosing regimen or formulations Dominik Heinzmann, PhD Global Development Team Leader Biostatistics Manager F. Hoffmann-La Roche,

More information

PROF. DR. MED. C. JACKISCH

PROF. DR. MED. C. JACKISCH PROF. DR. MED. C. JACKISCH Introduction of subcutaneous formulation: optimization of medcial unmet needs and hospital adminstration challenges from a physicians perspective Department of Obstetrics & Gynecology

More information

Subcutaneous (SQ) Hydration Augmented by Hyaluronidase

Subcutaneous (SQ) Hydration Augmented by Hyaluronidase Subcutaneous (SQ) Hydration Augmented by Hyaluronidase Reassess @ 60min Repeat Gorelick scale, VS PO challenge Repeat bolus? Dehydration Assessment with Gorelick Scale (see attached) > 4 wks of age Failed

More information

Halozyme Therapeutics, Inc.

Halozyme Therapeutics, Inc. Halozyme Therapeutics, Inc. The Next Chapter Begins: Creating Value Through Growth Jefferies 2014 Global Health Care Conference June 2014 Helen Torley, M.B. Ch. B., M.R.C.P. President and Chief Executive

More information

Present and emerging treatment options in Her-2/neu overexpressing metastatic breast cancer

Present and emerging treatment options in Her-2/neu overexpressing metastatic breast cancer Present and emerging treatment options in Her-2/neu overexpressing metastatic breast cancer Christoph C. Zielinski Clinical Division of Oncology, Department of Medicine I and Comprehensive Cancer Center,

More information

79956F Kitano et al_bi754091bi TiP_JSMO 2018 (NB).pdf 1 13/07/ :55:06 C M Y CM MY CY CMY K

79956F Kitano et al_bi754091bi TiP_JSMO 2018 (NB).pdf 1 13/07/ :55:06 C M Y CM MY CY CMY K 79956F Kitano et al_bi754091bi754111 TiP_JSMO 2018 (NB).pdf 1 13/07/2018 13:55:06 C M Y CM MY CY CMY K Phase 1 trial of an anti-pd-1 mab BI 754091 ± an anti-lag-3 mab BI 754111 in Asian patients with advanced

More information

LCA Breast Pathway 4 th Clinical Forum Systemic Treatments of Breast Cancer 3 rd December 2013

LCA Breast Pathway 4 th Clinical Forum Systemic Treatments of Breast Cancer 3 rd December 2013 LCA Breast Pathway 4 th Clinical Forum Systemic Treatments of Breast Cancer 3 rd December 2013 Welcome and LCA Breast Pathway Update Dr Will Teh, Chair - LCA Breast Pathway Group Thank you for coming today

More information

IMMUNOGLOBULIN REPLACEMENT THERAPY: ONE SIZE DOESN T FIT ALL

IMMUNOGLOBULIN REPLACEMENT THERAPY: ONE SIZE DOESN T FIT ALL PRIMARY IMMUNODEFICIENCIES IMMUNOGLOBULINS: ONE SIZE DOESN T FIT ALL IMMUNOGLOBULIN REPLACEMENT THERAPY: ONE SIZE DOESN T FIT ALL 1 PRIMARY IMMUNODEFICIENCIES ABBREVIATIONS IG IPOPI IV PID SC Immunoglobulins

More information

DEBRIDEMENT: ANATOMY and PHYSIOLOGY. Professor Donald G. MacLellan Executive Director Health Education & Management Innovations

DEBRIDEMENT: ANATOMY and PHYSIOLOGY. Professor Donald G. MacLellan Executive Director Health Education & Management Innovations DEBRIDEMENT: ANATOMY and PHYSIOLOGY Professor Donald G. MacLellan Executive Director Health Education & Management Innovations ANATOMY and PHYSIOLOGY Epidermal Layers ECM Structure Dermis Structure Skin

More information

Cell Walls, the Extracellular Matrix, and Cell Interactions (part 1)

Cell Walls, the Extracellular Matrix, and Cell Interactions (part 1) 14 Cell Walls, the Extracellular Matrix, and Cell Interactions (part 1) Introduction Many cells are embedded in an extracellular matrix which is consist of insoluble secreted macromolecules. Cells of bacteria,

More information

Positive HER-2 tumor. How to incorporate the new drugs into neoadjuvance

Positive HER-2 tumor. How to incorporate the new drugs into neoadjuvance Oncology Department Vall d Hebron University Hospital Barcelona. Spain Positive HER-2 tumor. How to incorporate the new drugs into neoadjuvance Javier Cortés June/2013 MD Anderson experience Buzdar et

More information

HALOZYME REPORTS SECOND QUARTER 2018 RESULTS

HALOZYME REPORTS SECOND QUARTER 2018 RESULTS Contacts: Robert H. Uhl Managing Director Westwicke Partners, LLC 858-356-5932 robert.uhl@westwicke.com Laurie Stelzer 858-704-8222 ir@halozyme.com FOR IMMEDIATE RELEASE HALOZYME REPORTS SECOND QUARTER

More information

Rituximab in the Treatment of NHL:

Rituximab in the Treatment of NHL: New Evidence reports on presentations given at ASH 2010 Rituximab in the Treatment of NHL: Rituximab versus Watch and Wait in Asymptomatic FL, R-Maintenance Therapy in FL with Standard or Rapid Infusion,

More information

Roche s subcutaneous formulation of MabThera approved in Switzerland for the treatment of common types of non-hodgkin lymphoma

Roche s subcutaneous formulation of MabThera approved in Switzerland for the treatment of common types of non-hodgkin lymphoma Media Release Basel, 12 January 2017 Roche s subcutaneous formulation of MabThera approved in Switzerland for the treatment of common types of non-hodgkin lymphoma Administration time significantly reduced

More information

Synopsis (C0524T12 GO LIVE)

Synopsis (C0524T12 GO LIVE) Protocol: EudraCT No.: 2005-003232-21 Title of the study: A Multicenter, Randomized, Double-blind, Placebo-controlled Trial of Golimumab, a Fully Human Anti-TNFα Monoclonal Antibody, Administered Intravenously,

More information

CRYSTALOMICS FORMULATION TECHNOLOGY

CRYSTALOMICS FORMULATION TECHNOLOGY CRYSTALOMICS FORMULATION TECHNOLOGY INTRODUCTION Over the past decade, protein-based therapeutics have emerged as a key driver of growth in the pharmaceutical industry. R&D pipelines have filled with biologics

More information

Connective Tissue (CT)

Connective Tissue (CT) Connective Tissue (CT) YONG-MEI CHEN ( 陈咏梅 ) Dept. of Anatomy, Histology & Embryology Peking Union Medical College Tel:69156461 E-mail address: pumc_he@126.com Content Introduction of CT 1. Origin 2. Compositions

More information

Denosumab (AMG 162) for bone metastases from solid tumours and multiple myeloma

Denosumab (AMG 162) for bone metastases from solid tumours and multiple myeloma Denosumab (AMG 162) for bone metastases from solid tumours and multiple myeloma September 2008 This technology summary is based on information available at the time of research and a limited literature

More information

Policy No: dru281. Medication Policy Manual. Date of Origin: September 24, Topic: Perjeta, pertuzumab. Next Review Date: May 2015

Policy No: dru281. Medication Policy Manual. Date of Origin: September 24, Topic: Perjeta, pertuzumab. Next Review Date: May 2015 Medication Policy Manual Topic: Perjeta, pertuzumab Committee Approval Date: May 9, 2014 Policy No: dru281 Date of Origin: September 24, 2012 Next Review Date: May 2015 Effective Date: June 1, 2014 IMPORTANT

More information

Ig Therapy: One Size Does Not Fit All

Ig Therapy: One Size Does Not Fit All Ig Therapy: One Size Does Not Fit All Carla Duff, CPNP, MSN, IgCN Advanced Registered Nurse Practitioner University of South Florida Division of Allergy, Immunology, and Rheumatology 1 Objectives Understand

More information

Most mammalian cells are located in tissues where they are surrounded by a complex extracellular matrix (ECM) often referred to as connective tissue.

Most mammalian cells are located in tissues where they are surrounded by a complex extracellular matrix (ECM) often referred to as connective tissue. GLYCOSAMINOGLYCANS Most mammalian cells are located in tissues where they are surrounded by a complex extracellular matrix (ECM) often referred to as connective tissue. The ECM contains three major classes

More information

NCCP Chemotherapy Regimen

NCCP Chemotherapy Regimen INDICATIONS FOR USE: Trastuzumab (IV) Monotherapy - 21 days Regimen *Reimbursement INDICATION ICD10 Code Status HER2 positive metastatic breast cancer (MBC) C50 00200a Hospital HER2 positive early breast

More information

TCHP Docetaxel, Carboplatin, Trastuzumab, Pertuzumab Neoadjuvant Protocol

TCHP Docetaxel, Carboplatin, Trastuzumab, Pertuzumab Neoadjuvant Protocol Systemic Anti Cancer Treatment Protocol TCHP Docetaxel, Carboplatin, Trastuzumab, Pertuzumab Neoadjuvant Protocol PROTOCOL REF: MPHATCHP (Version No: 1.0) Approved for use in: Neoadjuvant breast: The neoadjuvant

More information

Rituximab for subcutaneous delivery: Clinical management principles from a nursing perspective

Rituximab for subcutaneous delivery: Clinical management principles from a nursing perspective bs_bs_banner International Journal of Nursing Practice 2015; 21 (Suppl. 2), 1 13 SUPPLEMENT ARTICLE Rituximab for subcutaneous delivery: Clinical management principles from a nursing perspective Julia

More information

NCCP Chemotherapy Regimen. DOCEtaxel, CARBOplatin and Trastuzumab (TCH) - 21 days

NCCP Chemotherapy Regimen. DOCEtaxel, CARBOplatin and Trastuzumab (TCH) - 21 days DOCEtaxel, CARBOplatin and Trastuzumab (TCH) - 21 days INDICATIONS FOR USE: INDICATION ICD10 Regimen Code *Reimbursement Status Adjuvant treatment HER2 positive early breast cancer C50 00258a Hospital

More information

INTRATHECAL APPLICATION OF MONOCLONAL ANTIBODIES. Samo Rožman Institute of Oncology Ljubljana Slovenia

INTRATHECAL APPLICATION OF MONOCLONAL ANTIBODIES. Samo Rožman Institute of Oncology Ljubljana Slovenia INTRATHECAL APPLICATION OF MONOCLONAL ANTIBODIES Samo Rožman Institute of Oncology Ljubljana Slovenia AGENDA 1. INTRATHECAL APPLICATION 2. MONOCLONAL ANTIBODIES 3. MALIGNANT CARCINOMATOSIS 4. INTRATHECAL

More information

Hyaluronan Quantification Kit

Hyaluronan Quantification Kit Product manual (ELISA-like assay for HA / Hyaluronic Acid) Updated on Jan. 6th, 207 - Background Hyaluronan (HA) is an unbranched glycosaminoglycan composed of repeating disaccharide units of D-glucronic

More information

Sponsor: Sanofi Drug substance(s): SAR342434

Sponsor: Sanofi Drug substance(s): SAR342434 These results are supplied for informational purposes only. Prescribing decisions should be made based on the approved package insert in the country of prescription. Sponsor: Sanofi Drug substance(s):

More information

Pharmacokinetics and safety of subcutaneous rituximab in follicular lymphoma (SABRINA): stage 1 analysis of a randomised phase 3 study

Pharmacokinetics and safety of subcutaneous rituximab in follicular lymphoma (SABRINA): stage 1 analysis of a randomised phase 3 study Pharmacokinetics and safety of subcutaneous rituximab in follicular lymphoma (SABRINA): stage 1 analysis of a randomised phase 3 study Andrew Davies, Francesco Merli, Biljana Mihaljevic, Noppadol Siritanaratkul,

More information

Targeted Therapies in Metastatic Colorectal Cancer: An Update

Targeted Therapies in Metastatic Colorectal Cancer: An Update Targeted Therapies in Metastatic Colorectal Cancer: An Update ASCO 2007: Targeted Therapies in Metastatic Colorectal Cancer: An Update Bevacizumab is effective in combination with XELOX or FOLFOX-4 Bevacizumab

More information

CAM2038 A new liquid-lipid crystal depot buprenorphine: A dose-ranging suite of weekly and monthly subcutaneous depot injections

CAM2038 A new liquid-lipid crystal depot buprenorphine: A dose-ranging suite of weekly and monthly subcutaneous depot injections CAM2038 A new liquid-lipid crystal depot buprenorphine: A dose-ranging suite of weekly and monthly subcutaneous depot injections Dr. Fredrik Tiberg Assoc. Prof. President & CEO, Head R&D, Camurus Lund,

More information

Orencia (abatacept) for Rheumatoid Arthritis. Media backgrounder

Orencia (abatacept) for Rheumatoid Arthritis. Media backgrounder Orencia (abatacept) for Rheumatoid Arthritis Media backgrounder What is Orencia (abatacept)? Orencia (abatacept) is the first biologic agent to be available in both an intravenous (IV) and a self-injectable,

More information

Herceptin SC (Subcutaneous Trastuzumab)

Herceptin SC (Subcutaneous Trastuzumab) DRUG ADMINISTRATION SCHEDULE Day Drug Dose Route Rate 1 Herceptin SC (trastuzumab) 600mg S/C 2 to 5 mins *PRECAUTION: In order to reduce the risk of medication errors it is recommended that all trastuzumab

More information

Sponsor / Company: Sanofi Drug substance(s): insulin glargine (HOE901) According to template: QSD VERSION N 4.0 (07-JUN-2012) Page 1

Sponsor / Company: Sanofi Drug substance(s): insulin glargine (HOE901) According to template: QSD VERSION N 4.0 (07-JUN-2012) Page 1 These results are supplied for informational purposes only. Prescribing decisions should be made based on the approved package insert in the country of prescription. Sponsor / Company: Sanofi Drug substance(s):

More information

Update on the Management of HER2+ Breast Cancer. Christian Jackisch, MD, PhD Sana Klinikum Offenbach Offenbach, Germany

Update on the Management of HER2+ Breast Cancer. Christian Jackisch, MD, PhD Sana Klinikum Offenbach Offenbach, Germany Update on the Management of HER2+ Breast Cancer Christian Jackisch, MD, PhD Sana Klinikum Offenbach Offenbach, Germany Outline Treatment strategies for HER2-positive metastatic breast cancer since First

More information

Pharmacokinetic parameters: Halflife

Pharmacokinetic parameters: Halflife Pharmacokinetic parameters: Halflife (t 1/2 ) 1. By definition t 1/2 is the time required for the concentration to fall by one half. For drugs with first order kinetics this is a constant. 2. Half-life

More information

Roche provides update on phase III study of TECENTRIQ (atezolizumab) in people with previously treated advanced bladder cancer

Roche provides update on phase III study of TECENTRIQ (atezolizumab) in people with previously treated advanced bladder cancer Media Release Basel, 10 May 2017 Roche provides update on phase III study of TECENTRIQ (atezolizumab) in people with previously treated advanced bladder cancer IMvigor211 study did not meet its primary

More information

The clinical trial information provided in this public disclosure synopsis is supplied for informational purposes only.

The clinical trial information provided in this public disclosure synopsis is supplied for informational purposes only. The clinical trial information provided in this public disclosure synopsis is supplied for informational purposes only. Please note that the results reported in any single trial may not reflect the overall

More information

Il ruolo degli anticorpi anti farmaco nella pratica clinica

Il ruolo degli anticorpi anti farmaco nella pratica clinica Il ruolo degli anticorpi anti farmaco nella pratica clinica Daniela Pugliese, MD IBD Unit Complesso Integrato Columbus Gemelli Hospital Catholic University Foundation, Rome - Italy Therapeutic Drug monitoring

More information

Pharmacokinetics and safety of subcutaneous rituximab plus fludarabine and cyclophosphamide for patients with chronic lymphocytic leukaemia

Pharmacokinetics and safety of subcutaneous rituximab plus fludarabine and cyclophosphamide for patients with chronic lymphocytic leukaemia British Journal of Clinical Pharmacology DOI:10.1111/bcp.12662 Pharmacokinetics and safety of subcutaneous rituximab plus fludarabine and cyclophosphamide for patients with chronic lymphocytic leukaemia

More information

Glycosaminoglycans, Proteoglycans, and Glycoproteins

Glycosaminoglycans, Proteoglycans, and Glycoproteins Glycosaminoglycans, Proteoglycans, and Glycoproteins Presented by Dr. Mohammad Saadeh The requirements for the Pharmaceutical Biochemistry I Philadelphia University Faculty of pharmacy I. OVERVIEW OF GLYCOSAMINOGLYCANS

More information

Product: Denosumab (AMG 162) Clinical Study Report: month Primary Analysis Date: 21 November 2016 Page 1

Product: Denosumab (AMG 162) Clinical Study Report: month Primary Analysis Date: 21 November 2016 Page 1 Date: 21 November 2016 Page 1 2. SYNOPSIS Name of Sponsor: Amgen Inc., Thousand Oaks, CA, USA Name of Finished Product: Prolia Name of Active Ingredient: denosumab Title of Study: Randomized, Double-blind,

More information

An aldose contains an aldehyde functionality A ketose contains a ketone functionality

An aldose contains an aldehyde functionality A ketose contains a ketone functionality RCT Chapter 7 Aldoses and Ketoses; Representative monosaccharides. (a)two trioses, an aldose and a ketose. The carbonyl group in each is shaded. An aldose contains an aldehyde functionality A ketose contains

More information

This clinical study synopsis is provided in line with Boehringer Ingelheim s Policy on Transparency and Publication of Clinical Study Data.

This clinical study synopsis is provided in line with Boehringer Ingelheim s Policy on Transparency and Publication of Clinical Study Data. abcd Clinical Study Synopsis for Public Disclosure This clinical study synopsis is provided in line with s Policy on Transparency and Publication of Clinical Study Data. The synopsis which is part of the

More information

Investor Update. Downloads. Services PDF. Basel, 23 June 2017

Investor Update. Downloads. Services PDF. Basel, 23 June 2017 Investor Update Basel, 23 June 2017 FDA approves Rituxan Hycela (rituximab and hyaluronidase human) for subcutaneous injection in certain blood cancers Treatment can be administered in five to seven minutes,

More information

Pharmacology Updates in Breast Cancer Chris Vaklavas, M.D.

Pharmacology Updates in Breast Cancer Chris Vaklavas, M.D. Pharmacology Updates in Breast Cancer Chris Vaklavas, M.D. Assistant Professor Department of Medicine, Division of Hematology/Oncology University of Alabama at Birmingham NP2540M 1802 6th Avenue South

More information

Xiaoping (Amy) Zhang, Varun Goel, Husain Attarwala, and Gabriel Robbie. Alnylam Pharmaceuticals, Cambridge, USA

Xiaoping (Amy) Zhang, Varun Goel, Husain Attarwala, and Gabriel Robbie. Alnylam Pharmaceuticals, Cambridge, USA Patisiran Pharmacokinetics (PK), Pharmacodynamics (PD), and Exposure-Response (E-R) Relationship in Patients with Hereditary Transthyretin-Mediated (hattr) Amyloidosis Xiaoping (Amy) Zhang, Varun Goel,

More information

Subcutaneous Immune Globulin: Alternative Therapeutic Pathway for Patients With Primary Immunodeficiency

Subcutaneous Immune Globulin: Alternative Therapeutic Pathway for Patients With Primary Immunodeficiency Subcutaneous Immune Globulin: Alternative Therapeutic Pathway for Patients With Primary Immunodeficiency EDUCATIONAL OBJECTIVES Upon completion of this program, participants should be better able to: 1.

More information

PRO: Pathologic Complete Response Does Predict Outcome for Early Stage Breast Cancer Patients

PRO: Pathologic Complete Response Does Predict Outcome for Early Stage Breast Cancer Patients PRO: Pathologic Complete Response Does Predict Outcome for Early Stage Breast Cancer Patients Amelia B. Zelnak, M.D., M.Sc. Assistant Professor of Hematology and Medical Oncology Winship Cancer Institute

More information

pan-canadian Oncology Drug Review Final Economic Guidance Report Pertuzumab (Perjeta) Neoadjuvant Breast Cancer July 16, 2015

pan-canadian Oncology Drug Review Final Economic Guidance Report Pertuzumab (Perjeta) Neoadjuvant Breast Cancer July 16, 2015 pan-canadian Oncology Drug Review Final Economic Guidance Report Pertuzumab (Perjeta) Neoadjuvant Breast Cancer July 16, 2015 DISCLAIMER Not a Substitute for Professional Advice This report is primarily

More information

This clinical study synopsis is provided in line with Boehringer Ingelheim s Policy on Transparency and Publication of Clinical Study Data.

This clinical study synopsis is provided in line with Boehringer Ingelheim s Policy on Transparency and Publication of Clinical Study Data. abcd Clinical Study Synopsis for Public Disclosure This clinical study synopsis is provided in line with s Policy on Transparency and Publication of Clinical Study Data. The synopsis which is part of the

More information

Novel Formulations to Modify Mealtime Insulin Kinetics

Novel Formulations to Modify Mealtime Insulin Kinetics Novel Formulations to Modify Mealtime Insulin Kinetics Alan Krasner, Roderike Pohl, Patrick Simms, Philip Pichotta, Robert Hauser, Errol De Souza Biodel, Inc. Danbury, CT Disclosure All authors are employees

More information

Vol. 38 No. 5 November 2009 Journal of Pain and Symptom Management 663

Vol. 38 No. 5 November 2009 Journal of Pain and Symptom Management 663 Vol. 38 No. 5 November 29 Journal of Pain and Symptom Management 663 Original Article The INFUSE-Morphine Study: Use of Recombinant Human Hyaluronidase (rhuph2) to Enhance the Absorption of Subcutaneously

More information

2014 San Antonio Breast Cancer Symposium Review

2014 San Antonio Breast Cancer Symposium Review 2014 San Antonio Breast Cancer Symposium Review HER2 Positive Disease 01-10-2015 Elisavet Paplomata, MD Assistant Professor Hematology & Medical Oncology Emory University Winship Cancer Institute S6-01

More information

Assay Kit for Measurement of Proteoglycan. (Sulfated Glycosaminoglycan Quantification Kit)

Assay Kit for Measurement of Proteoglycan. (Sulfated Glycosaminoglycan Quantification Kit) Assay Kit for Measurement of Proteoglycan. (Sulfated Glycosaminoglycan Quantification Kit) Cat. No. 280560-N INTRODUCTION Glycosaminoglycans (GAGs) are a major component of the extracellular matrix (ECM)

More information

Single Agent Activity of ZW25, a HER2-Targeted Bispecific Antibody, in Heavily Pretreated HER2-Expressing Cancers

Single Agent Activity of ZW25, a HER2-Targeted Bispecific Antibody, in Heavily Pretreated HER2-Expressing Cancers Single Agent Activity of ZW25, a HER2-Targeted Bispecific Antibody, in Heavily Pretreated HER2-Expressing Cancers 1, Murali Beeram 2, Jose Mayordomo 3, Diana Hanna 4, Jaffer Ajani 1, Mariela Blum Murphy

More information

Scottish Medicines Consortium

Scottish Medicines Consortium P Oral) Scottish Medicines Consortium vinorelbine 20 and 30mg capsules (NavelbineP Pierre Fabre Ltd No. (179/05) 06 May 2005 The Scottish Medicines Consortium (SMC) has completed its assessment of the

More information

HER2-positive Breast Cancer

HER2-positive Breast Cancer HER2-positive Breast Cancer Multiple choices what to use when? Thomas Ruhstaller Brustzentrum St. Gallen Adjuvant setting NCIC MA5 N Engl J Med 06, 2103 6 x CEF can 6 x CMF oral HER2 + pg schlecht in allen

More information

Sponsor/Company: sanofi-aventis Drug substance: Elitek/Fasturtec (rasburicase, SR29142)

Sponsor/Company: sanofi-aventis Drug substance: Elitek/Fasturtec (rasburicase, SR29142) These results are supplied for informational purposes only. Prescribing decisions should be made based on the approved package insert in the country of prescription. Sponsor/Company: sanofi-aventis Drug

More information

This clinical study synopsis is provided in line with Boehringer Ingelheim s Policy on Transparency and Publication of Clinical Study Data.

This clinical study synopsis is provided in line with Boehringer Ingelheim s Policy on Transparency and Publication of Clinical Study Data. abcd Clinical Study for Public Disclosure This clinical study synopsis is provided in line with s Policy on Transparency and Publication of Clinical Study Data. The synopsis which is part of the clinical

More information

Van Cutsem E et al. Proc ASCO 2009;Abstract LBA4509.

Van Cutsem E et al. Proc ASCO 2009;Abstract LBA4509. Efficacy Results from the ToGA Trial: A Phase III Study of Trastuzumab Added to Standard Chemotherapy in First-Line HER2- Positive Advanced Gastric Cancer Van Cutsem E et al. Proc ASCO 2009;Abstract LBA4509.

More information

Third Quarter 2015 Earnings Call. November 9, 2015

Third Quarter 2015 Earnings Call. November 9, 2015 Third Quarter 2015 Earnings Call November 9, 2015 Forward-Looking Statements All of the statements in this presentation that are not statements of historical facts constitute forward-looking statements

More information

Glycosaminoglycans: Anionic polysaccharide chains made of repeating disaccharide units

Glycosaminoglycans: Anionic polysaccharide chains made of repeating disaccharide units Glycosaminoglycans: Anionic polysaccharide chains made of repeating disaccharide units Glycosaminoglycans present on the animal cell surface and in the extracellular matrix. Glycoseaminoglycans (mucopolysaccharides)

More information

NIH Public Access Author Manuscript Transplant Proc. Author manuscript; available in PMC 2010 September 22.

NIH Public Access Author Manuscript Transplant Proc. Author manuscript; available in PMC 2010 September 22. NIH Public Access Author Manuscript Published in final edited form as: Transplant Proc. 1990 February ; 22(1): 57 59. Effect of Hepatic Dysfunction and T Tube Clamping on FK 506 Pharmacokinetics and Trough

More information

Current and Future perspectives of HER2+ BC

Current and Future perspectives of HER2+ BC 2018.4.6 GBCC Satellite symposium Current and Future perspectives of HER2+ BC Jee Hyun Kim, M.D., Ph.D. Seoul National University Bundang Hospital Seoul National University College of Medicine Disclaimer

More information

The next wave of successful drug therapy strategies in HER2-positive breast cancer. Hans Wildiers University Hospitals Leuven Belgium

The next wave of successful drug therapy strategies in HER2-positive breast cancer. Hans Wildiers University Hospitals Leuven Belgium The next wave of successful drug therapy strategies in HER2-positive breast cancer Hans Wildiers University Hospitals Leuven Belgium Trastuzumab in 1st Line significantly improved the prognosis of HER2-positive

More information

Her 2 Positive Metastatic Breast Cancer

Her 2 Positive Metastatic Breast Cancer Her 2 Positive Metastatic Breast Cancer Alison Jones November 2013 Mrs Hermione Positive (then and now!) Diagnosed 2007 T2 N1 Mo ER ve; Her2 ve Mastectomy ANC; FEC/T Herceptin (12months) August 2010metastatic

More information

Office based non-oncology urology trials Richard W. Casey, MD, 1 Jack Barkin, MD 2

Office based non-oncology urology trials Richard W. Casey, MD, 1 Jack Barkin, MD 2 Office based non-oncology urology trials Richard W. Casey, MD, 1 Jack Barkin, MD 2 1 The Male Health Centre, Oakville, Ontario, Canada 2 Humber River Regional Hospital, University of Toronto, Toronto,

More information

NCCP Chemotherapy Regimen

NCCP Chemotherapy Regimen INDICATIONS FOR USE: Pembrolizumab 2mg/kg INDICATION ICD10 Regimen Code *Reimbursement Status First line monotherapy for the treatment of advanced (unresectable or C43 00347a ODMS metastatic) melanoma

More information

Scottish Medicines Consortium

Scottish Medicines Consortium Scottish Medicines Consortium ustekinumab, 45mg solution for injection (Stelara ) No. (572/09) Janssen-Cilag Ltd 15 January 2010 The Scottish Medicines Consortium (SMC) has completed its assessment of

More information

AT Hickerson 1, GT Clifton 1, DF Hale 1, KM Peace 1, JP Holmes 2, TJ Vreeland 3, JK Litton 4, RK Murthy 4, KK Lukas 5, EA Mittendorf 6, GE Peoples 7

AT Hickerson 1, GT Clifton 1, DF Hale 1, KM Peace 1, JP Holmes 2, TJ Vreeland 3, JK Litton 4, RK Murthy 4, KK Lukas 5, EA Mittendorf 6, GE Peoples 7 Final analysis of Nelipepimut-S plus GM-CSF with trastuzumab versus GM-CSF with trastuzumab to prevent recurrences in high-risk, HER2 low-expressing breast cancer: a prospective, randomized, blinded multicenter

More information

PRACTICAL APPLICATION INSTYLAN MODERN PROTECTOR OF URINARY BLADDER MUCOSA

PRACTICAL APPLICATION INSTYLAN MODERN PROTECTOR OF URINARY BLADDER MUCOSA PRACTICAL APPLICATION INSTYLAN MODERN PROTECTOR OF URINARY BLADDER MUCOSA E.O. Stakhovsky, PhD, MD, Professor, Head of the Scientific and Research Department of Plastic and Reconstructive Oncourology,

More information

Comparison of nasogastric and intravenous methods of rehydration in pediatric patients with acute dehydration Nager A L, Wang V J

Comparison of nasogastric and intravenous methods of rehydration in pediatric patients with acute dehydration Nager A L, Wang V J Comparison of nasogastric and intravenous methods of rehydration in pediatric patients with acute dehydration Nager A L, Wang V J Record Status This is a critical abstract of an economic evaluation that

More information

A Randomized, Double-Blind, Placebo-Controlled, Phase 3 Study of the Safety and Analgesic Efficacy of MNK-795 Controlled-Release

A Randomized, Double-Blind, Placebo-Controlled, Phase 3 Study of the Safety and Analgesic Efficacy of MNK-795 Controlled-Release A Randomized, Double-Blind, Placebo-Controlled, Phase 3 Study of the Safety and Analgesic Efficacy of MNK-795 Controlled-Release Oxycodone/Acetaminophen Tablets (CR OC/APAP) in an Acute Pain Model Neil

More information

Update in the treatment of Her2- overexpressing breast cancers. Fabrice ANDRE Institut Gustave Roussy Villejuif, France

Update in the treatment of Her2- overexpressing breast cancers. Fabrice ANDRE Institut Gustave Roussy Villejuif, France Update in the treatment of Her2- overexpressing breast cancers Fabrice ANDRE Institut Gustave Roussy Villejuif, France Questions Should tumors

More information

Roche s Perjeta regimen approved in Europe for use before surgery in early stage aggressive breast cancer

Roche s Perjeta regimen approved in Europe for use before surgery in early stage aggressive breast cancer Media Release Basel, 31 July, 2015 Roche s Perjeta regimen approved in Europe for use before surgery in early stage aggressive breast cancer The approval is based on the benefit seen with the Perjeta regimen

More information

Herceptin IV (Trastuzumab) and Paclitaxel Cumbria, Northumberland, Tyne & Wear Area Team

Herceptin IV (Trastuzumab) and Paclitaxel Cumbria, Northumberland, Tyne & Wear Area Team DRUG ADMINISTRATION SCHEDULE Given as a three weekly schedule Day Drug Daily Dose Route Diluent & Rate On first cycle 250mls Normal Saline Herceptin IV 8 mg/kg Infusion only 90 mins On other 250mls Normal

More information

Next Generation Therapeutics for Disorders of Complement Regulation

Next Generation Therapeutics for Disorders of Complement Regulation Next Generation Therapeutics for Disorders of Complement Regulation March 2018 Forward Looking Statements This presentation contains "forward-looking statements" within the meaning of the Private Securities

More information

FEC-T plus trastuzumab & pertuzumab

FEC-T plus trastuzumab & pertuzumab Page 1 of 5 Indication Treatment Intent Frequency and number of cycles Monitoring parameters pre-treatment The neoadjuvant treatment of locally advanced, inflammatory or early HER2 positive breast cancer

More information

The clinical trial information provided in this public disclosure synopsis is supplied for informational purposes only.

The clinical trial information provided in this public disclosure synopsis is supplied for informational purposes only. The clinical trial information provided in this public disclosure synopsis is supplied for informational purposes only. Please note that the results reported in any single trial may not reflect the overall

More information

Factors impacting the SC bioavailability of therapeutic antibodies

Factors impacting the SC bioavailability of therapeutic antibodies Factors impacting the SC bioavailability of therapeutic antibodies How can we improve it? Saileta Prabhu 19 May 2014 SC bioavailability (%) of therapeutic antibodies in humans varies to a large extent

More information

Current situation and future of renal anemia treatment. FRANCESCO LOCATELLI

Current situation and future of renal anemia treatment. FRANCESCO LOCATELLI Antalya May 20, 2010 12 National Congress of Turkish Society of Hypertension and Renal Disease Current situation and future of renal anemia treatment. FRANCESCO LOCATELLI Department of Nephrology, Dialysis

More information

Media Release. Basel, 26 March 2018

Media Release. Basel, 26 March 2018 Media Release Basel, 26 March 2018 Phase III IMpower150 study showed Roche s TECENTRIQ (atezolizumab) and Avastin (bevacizumab) plus carboplatin and paclitaxel helped people with advanced lung cancer live

More information

TransCon CNP: Preliminary Phase 1 Data. November 28, 2018

TransCon CNP: Preliminary Phase 1 Data. November 28, 2018 TransCon CNP: Preliminary Phase Data November 28, 28 Normal Growth Depends on Balanced Pathways CNP Activity FGFR3 Activity FGFR3 CNP FGFR3 CNP Normal growth Achondroplasia growth TransCon CNP is designed

More information

METRIC Study Key Eligibility Criteria

METRIC Study Key Eligibility Criteria The METRIC Study METRIC Study Key Eligibility Criteria The pivotal METRIC Study is evaluating glembatumumab vedotin in patients with gpnmb overexpressing metastatic triple-negative breast cancer (TNBC).

More information

4. Aflibercept showed significant improvement in overall survival (OS), the primary

4. Aflibercept showed significant improvement in overall survival (OS), the primary Cost effectiveness of aflibercept (Zaltrap ) in combination with FOLFIRI in the treatment of adult patients with metastatic colorectal cancer (mcrc) that is resistant to or has progressed after an oxaliplatin

More information

Name of Active Ingredient: Fully human monoclonal antibody to receptor activator for nuclear factor-κb ligand

Name of Active Ingredient: Fully human monoclonal antibody to receptor activator for nuclear factor-κb ligand Page 2 of 1765 2. SYNOPSIS Name of Sponsor: Amgen Inc. Name of Finished Product: Denosumab (AMG 162) Name of Active Ingredient: Fully human monoclonal antibody to receptor activator for nuclear factor-κb

More information

Triple Negative Breast cancer New treatment options arenowhere?

Triple Negative Breast cancer New treatment options arenowhere? Triple Negative Breast cancer New treatment options arenowhere? Ofer Rotem, M.D., B.Sc. Breast Unit, Davidoff center Rabin Medical center October 2017 Case 6/2013 - M.D., 38 years old woman, healthy, no

More information

2

2 1 2 Systematic review of published evidence PUBMED 1999-2017 ASCO 1999-2017 SABCS 1999-2017 ECCO/ESMO 1999-2017 3 Statement: Anthracycline/ taxane based chemotherapy 1. Budd GT et al. SWOG S0221: A Phase

More information

Phase I and Pharmacodynamic Study of High-Dose NGR-hTNF in Patients

Phase I and Pharmacodynamic Study of High-Dose NGR-hTNF in Patients Phase I and Pharmacodynamic Study of High-Dose NGR-hTNF in Patients with Refractory Solid Tumors P. A. Zucali 1, A. Santoro 1, M. Simonelli 1, F. De Vincenzo 1, E. Lorenzi 1, L. Rimassa 1, L. Balzarini

More information

Clinical Commissioning Policy: Chemotherapy Algorithms for Adults and Children. January 2013 Reference: NHS England XXX/X/X.

Clinical Commissioning Policy: Chemotherapy Algorithms for Adults and Children. January 2013 Reference: NHS England XXX/X/X. Clinical Commissioning Policy: Chemotherapy Algorithms for Adults and Children January 2013 Reference: NHS England XXX/X/X England 1 NHS England Clinical Commissioning Policy: Chemotherapy Algorithms for

More information

Clinical Trial List

Clinical Trial List Clinical Trial List 2005 2008 Service Driven. Quality Focused. Global Perspective. Clinical Trial List 2005-2008 1 Pharmacokinetic A Two-Period, Single Dose Pharmacokinetic Study of Three Sustained-Release

More information

PROMISE 2 Top-Line Data Results January 8, 2018

PROMISE 2 Top-Line Data Results January 8, 2018 PROMISE 2 Top-Line Data Results January 8, 2018 Forward-Looking Statements This presentation and the accompanying commentary contains certain forward-looking statements within the meaning of Section 27A

More information

Essais de supériorité / d équivalence / de non-infériorité. Prof. X Pivot

Essais de supériorité / d équivalence / de non-infériorité. Prof. X Pivot Essais de supériorité / d équivalence / de non-infériorité Prof. X Pivot Confidence interval 95% Superiority P=0,002 P=0,05 HR 0,75 (95%CI: 0,90 0,50) HR 0,80 (95%CI: 1 0,65) 1 Ratio of events over the

More information

All Studies by Indication

All Studies by Indication Therapeutic Area Protocol Number Drug/Device Phase Description Advanced malignancies 337 20101132 AMG 337 I " A Phase 1, First-in-Human Study Evaluating the Safety, Tolerability, and Pharmacokinetics of

More information

Pharmacokinetics in the critically ill. Intensive Care Training Program Radboud University Medical Centre Nijmegen

Pharmacokinetics in the critically ill. Intensive Care Training Program Radboud University Medical Centre Nijmegen Pharmacokinetics in the critically ill Intensive Care Training Program Radboud University Medical Centre Nijmegen In general... Critically ill patients are at higher risk for ADE s and more severe ADE

More information

BC Cancer Protocol Summary for Treatment of Chronic Lymphocytic Leukemia or Prolymphocytic Leukemia with Fludarabine and rituximab

BC Cancer Protocol Summary for Treatment of Chronic Lymphocytic Leukemia or Prolymphocytic Leukemia with Fludarabine and rituximab BC Cancer Protocol Summary for Treatment of Chronic Lymphocytic Leukemia or Prolymphocytic Leukemia with Fludarabine and rituximab Protocol Code Tumour Group Contact Physicians LYCLLFLUDR Lymphoma Dr.

More information

Infographic (right): ESMO 2014 record breaking Congress

Infographic (right): ESMO 2014 record breaking Congress ESMO 2014 Congress Scientific Meeting Report Supportive and Palliative Care Extract 26-30 September 2014 Madrid, Spain Summary The European Society for Medical Oncology (ESMO) Congress, held September

More information

Locally Advanced Breast Cancer: Systemic and Local Therapy

Locally Advanced Breast Cancer: Systemic and Local Therapy Locally Advanced Breast Cancer: Systemic and Local Therapy Joseph A. Sparano, MD Professor of Medicine & Women s Health Albert Einstein College of Medicine Associate Chairman, Department of Oncology Montefiore

More information

Modeling and Simulation to Support Development and Approval of Complex Products

Modeling and Simulation to Support Development and Approval of Complex Products Modeling and Simulation to Support Development and Approval of Complex Products Mathangi Gopalakrishnan, MS, PhD Research Assistant Professor Center for Translational Medicine, School of Pharmacy, UMB

More information